Johnson & Johnson (JNJ) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Shares of this world's biggest maker of health care products have returned +2.7% over the past month versus the Zacks S&P 500 composite's +3.5% change. The Zacks Large Cap Pharmaceuticals industry, to which Johnson & Johnson belongs, has gained 8.6% over this period. Now the key question is: Where could the stock b ...

Coca-Cola and Other Dividend Kings That Have Raised Their Payouts for 60 Years or More ...

Johnson & Johnson (JNJ) closed the most recent trading day at $161.63, moving +0.06% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 0.15%. On the other hand, the Dow registered a loss of 0.42%, and the technology-centric Nasdaq increased by 0.09%.Prior to today's trading, shares of the world's biggest maker of health care products had gained 4.17% over the past month. This has lagged the Medical sector's gain of 6.58% and outpaced the S&P 500's gain of 3. ...

业绩总结 - 2023年是Johnson & Johnson非常有成效的一年，公司的增长率接近7%[3] - 在医药领域，公司的调整后运营增长率为6.5%，医疗技术领域为7.5%[3] - Johnson & Johnson计划在2024年实现5%至6%的收入增长，2025年为3%[8] - 到2030年，公司预计医药部门的年增长率将达到5%至7%[9] 新产品和新技术研发 - 公司计划在未来十年内推出10种潜在销售额超过50亿美元的产品[13] - 新的口服肽在牛皮癣领域展现出与注射生物制剂相媲美的疗效，市场潜力从10亿美元增长至50亿美元[28] - 公司在医疗技术领域取得了7.5%的调整运营增长，目标是在市场的高端实现增长[33] 市场扩张和并购 - 公司收购Ambrx，将ADCs引入固体肿瘤领域，看好其在前列腺癌领域的潜力[55] - 公司的BD战略聚焦在具备内部能力和专业知识的领域，如肿瘤学、免疫学和神经科学[62] 未来展望 - 公司计划通过创新来提高MedTech业务的销售额，预计到2027年将有三分之一的销售额来自新产品[15] - 公司提供了2024年的指导，预计调整运营收入增长5%至6%，EPS增长7.3%[43]

公司定位和业务发展 - 公司在2023年举行了企业业务审查日，首次展示了全新的公司定位，专注于医疗技术和药品创新[2] - 公司将专注于医疗技术和药品领域，以提高增长潜力、利润率和专业化水平，同时保持规模和多样性[3] - 公司在医药和医疗技术领域均取得了强劲增长，销售增长率达到了7%[3] 医药领域发展 - 公司在医药领域取得了重要进展，如TALVEY的批准、CARVYKTI的进展以及其他重要数据的发布[4] - 公司对多发性骨髓瘤领域的重视，预计到2030年，该领域的销售额将超过250亿美元，公司将占据50%的患者治疗份额[26] - 公司对口服IL-23产品J&J 2113的销售预期提高，看好其在免疫学领域的竞争优势和市场表现[27] 医疗技术领域发展 - 公司进行了一项早期收购，以进入左心耳附件设备市场[5] - 公司在医疗技术领域取得了显著增长，从2017年的全球1.5%增长到2023年前九个月的7.5%[33] - 公司在医疗技术领域继续取得进展，包括收购Abiomed公司，该交易的业务表现超出了预期[38] 未来展望和战略规划 - 公司对2023年的业绩感到自信，预计能够实现提供的业绩指引[6] - 公司设定了未来几年的增长目标，包括医药集团在2024年的营收增长为5%至6%，并计划在2025年至2030年实现5%至7%的年复合增长率[8] - 公司提供了2024年的指导意见，预计调整后运营收入增长5%至6%，EPS增长7.3%，并计划在制药领域继续扩大核心品牌并在医疗技术领域推出新产品和进行重组计划[43]

Key TakeawaysJohnson & Johnson said Monday that it bought Ambrx Biopharma for about $2 billion to boost its oncology portfolio.The $28-per-share all-cash offer is at a 105% premium to Ambrx's closing price on Friday.Ambrx's clinical and preclinical treatments use antibody drug coagulates to attack a variety of cancer cells.Ambrx shares more than doubled following the news, hitting an all-time high.Ambrx Biopharma Inc. (AMAM) shares more than doubled Monday on news that Johnson & Johnson (J&J) (JNJ) would pu ...

ToplineJohnson & Johnson will pay an estimated $700 million to resolve an investigation by more than 40 states into the pharmaceutical firm’s marketing of its talcum powder, according to Bloomberg, following thousands of lawsuits alleging it failed to warn customers about cancer risks.The pharmaceutical firm faces thousands of lawsuits alleging its talcum powder poses cancer risks. Getty Images Key FactsThe tentative agreement will end an ongoing probe into Johnson & Johnson’s talcum-based baby powder and w ...

Proactive团队 - Angela Harmantas是Proactive的编辑，拥有超过15年的股票市场报道经验，专注于北美的初级资源股[2] - Proactive的金融新闻团队在全球的金融和投资中心设有办事处和工作室，包括伦敦、纽约、多伦多、温哥华、悉尼和珀斯[4] - Proactive团队专注于中小市值市场，同时也关注蓝筹公司、大宗商品和更广泛的投资故事，为激发和吸引有动力的私人投资者提供内容[5] Proactive团队的报道范围 - Proactive团队提供跨市场的新闻和独特见解，包括生物技术和制药、矿业和自然资源、电池金属、石油和天然气、加密货币以及新兴数字和电动车技术[6] Proactive团队的工作流程 - Proactive始终是一个前瞻性和热情的技术采用者，团队拥有许多年有价值的专业知识和经验，同时也利用技术来辅助和增强工作流程[7] - Proactive偶尔会使用自动化和软件工具，包括生成式人工智能，但所有由Proactive发布的内容都是由人类编辑和撰写的，符合内容制作和搜索引擎优化的最佳实践[8]

BlackJack3DStelara, Johnson & Johnson's (NYSE:JNJ) leading product, is nearing the end of its exclusivity outside the US by mid-2024 and in the US by early 2025. Stelara is a significant part of JNJ's sales and operating income, making up about 13% of total sales and 24% of operating income in 2023. This loss of exclusivity will likely slow down the growth of earnings per share (EPS) for JNJ, which is a shift from their previous aim of growing EPS faster than sales. Analysts currently predict declines o ...

Mario Tama Dear readers, Johnson & Johnson (NYSE:JNJ) is arguably one of the safest businesses in the world, as it is one of only two companies that have an AAA rating which is higher than the AA+ rating of the U.S. government. It is also a dividend king with a 60+ year history of dividend increases and a defensive stock which I believe is suitable for most portfolios. I argued in a recent article on Procter & Gamble (PG) why I like to allocate a portion of my capital to Staples. JNJ shares a lot of the sam ...